Animas licenses Debiotech's insulin pump technology
This article was originally published in Clinica
Executive Summary
Swiss microtechnology expert Debiotech has granted US insulin pump maker Animas exclusive worldwide rights to new developments in insulin pumps and needles. The Lausanne-based firm will receive $12m in cash up front and stands to receive an additional $2m milestone payment plus royalties.